BioMarin
BioMarin’s Brineura Receives Significant Label Expansion from FDA for Children Under 3 with CLN2 Disease
BioMarin, Brineura, FDA, Label Expansion, CLN2 Disease, Children Under 3, Cerliponase Alfa, Intraventricular Injection, Motor Ability Deterioration, Neurodegenerative Symptoms
BioMarin Downsizes Workforce Amidst Strategic R&D Shift
BioMarin, job cuts, R&D refocus, biotechnology, strategic shift, workforce reduction